Physician profile
Iqbal Bashir
NPI 1699793539
$4,893.10
in general payments reported to CMS, 2019-2025
19 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2021: $150 · 2022: $33.73 · 2023: $364 · 2024: $3,769 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,212 · Food and Beverage: $1,383 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,211.82 |
| Food and Beverage | $1,382.86 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,540.12 | 2023-2025 | Aveir, Cardiomems |
| Shockwave Medical, INC | $278.33 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $261.51 | 2019-2025 | |
| Baxter Healthcare | $151.06 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Artivion, INC. | $149.95 | 2021 | |
| Pfizer INC. | $104.35 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $72.70 | 2023-2024 | Verquvo |
| Amgen INC. | $50.37 | 2023-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $49.45 | 2024-2025 | Camzyos |
| Cvrx, INC. | $46.09 | 2025 | Barostim Neo System |
| Irhythm Technologies, INC. | $40.14 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $28.38 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $26.97 | 2025 | Wainua |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2022 | |
| Lantheus Medical Imaging, INC. | $16.29 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.88 | 2025 | Wegovy |
| Altathera Pharmaceuticals LLC | $14.69 | 2025 | Sotalol Hydrochloride |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $13.48 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.